US Patent

US8329692 — Pyrimidinyl pyridazinone derivatives

Composition of Matter · Assigned to Merck Patent GmbH · Expires 2029-10-30 · 3y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a group of pyrimidinyl pyridazinone derivatives that inhibit tyrosine kinases, particularly Met kinase.

USPTO Abstract

Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US8329692
Jurisdiction: US
Classification: Composition of Matter
Expires: 2029-10-30
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.